Boehringer Ingelheim registers Phase Ib/II trial pairing obrixtamig with Zai Lab's ZL-1310 in SCLC
Boehringer Ingelheim's DAREON-36 study, listed July 16, 2026, will test obrixtamig plus ZL-1310 with or without atezolizumab in advanced neuroendocrine cancers.
Boehringer Ingelheim posted one new registry record this week.
- A Phase Ib/II trial called "DAREON-36" (NCT07707895) is not yet recruiting, sponsored by Boehringer Ingelheim with Zai Lab as a collaborator.1 The study plans to enroll 60 participants across small cell lung cancer and related neuroendocrine carcinomas1 and is designed first to find a suitable dose of obrixtamig combined with ZL-1310, then to test tolerability of that combination with the checkpoint inhibitor atezolizumab.1 Estimated start is October 19, 2026, with primary completion estimated for April 26, 2030.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.